Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives -: I.: Structure-activity relationships on the terminal peptidic moiety

被引:16
作者
Hasuoka, A
Nishikimi, Y
Nakayama, Y
Kamiyama, K
Nakao, M
Miyagawa, KI
Nishimura, O
Fujino, M
机构
[1] Takeda Chem Ind Ltd, Div Pharmaceut Res, Med Chem Res Labs 1, Yodogawa Ku, Osaka 5328686, Japan
[2] Takeda Chem Ind Ltd, Mkt Div, Vaccine Grp, Chuo Ku, Osaka 5408645, Japan
[3] Takeda Chem Ind Ltd, Div Pharmaceut Res, Pharmaceut Discovery Ctr, Yodogawa Ku, Osaka 5328686, Japan
[4] Takeda Chem Ind Ltd, Div Pharmaceut Res, Tsukuba, Ibaraki 3004293, Japan
关键词
D O I
10.7164/antibiotics.55.322
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The novel natural antibiotics pyloricidin A, B and C possess potent and highly selective antibacterial activity against Helicobacter pylori. In order to investigate the structure activity relationships for the terminal peptidic moiety, a series of pyloricidin B and pyloricidin C derivatives, bearing various amino acids in the moiety, were prepared and evaluated for their anti-H. pylori activity. The derivatives bearing alpha-D-, beta- and gamma-amino acids or peptidemimetics showed drastically decreased activity. On the other hand, the derivatives with alpha-L-amino acids were found to maintain the activity. Among the derivatives prepared in this work, the allylglycine derivative 2s showed the most potent anti-H. pylori activity, with an MIC value of less than 0.006 mug/ml against H. pylori NCTC11637, which is 60-fold greater than the activity of the lead compound pyloricidin C.
引用
收藏
页码:322 / 336
页数:15
相关论文
共 16 条
  • [1] DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS
    BAYERDORFFER, E
    MIEHLKE, S
    MANNES, GA
    SOMMER, A
    HOCHTER, W
    WEINGART, J
    HELDWEIN, W
    KLANN, H
    SIMON, T
    SCHMITT, W
    BASTLEIN, E
    EIMILLER, A
    HATZ, R
    LEHN, N
    DIRSCHEDL, P
    STOLTE, M
    [J]. GASTROENTEROLOGY, 1995, 108 (05) : 1412 - 1417
  • [2] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [3] BELL GD, 1995, ALIMENT PHARM THERAP, V9, P41
  • [4] FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676
  • [5] FUJINO M, 1974, CHEM PHARM BULL, V22, P1857
  • [6] TREATMENT OF PEPTIC-ULCERS CAUSED BY HELICOBACTER-PYLORI
    GRAHAM, DY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (05) : 349 - 350
  • [7] FACTORS INFLUENCING THE ERADICATION OF HELICOBACTER-PYLORI WITH TRIPLE THERAPY
    GRAHAM, DY
    LEW, GM
    MALATY, HM
    EVANS, DG
    EVANS, DJ
    KLEIN, PD
    ALPERT, LC
    GENTA, RM
    [J]. GASTROENTEROLOGY, 1992, 102 (02) : 493 - 496
  • [8] SIMPLE SYNTHESIS OF L-VINYLGLYCINE AND D-VINYLGLYCINE (2-AMINOBUT-3-ENOIC ACID) AND RELATED AMINO-ACIDS
    HALLINAN, KO
    CROUT, DHG
    ERRINGTON, W
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1994, (24): : 3537 - 3543
  • [9] Total synthesis of novel antibiotics pyloricidin A, B and C and their application in the study of pyloricidin derivatives
    Hasuoka, A
    Nishikimi, Y
    Nakayama, Y
    Kamiyama, K
    Nakao, M
    Miyagawa, K
    Nishimura, O
    Fujino, M
    [J]. JOURNAL OF ANTIBIOTICS, 2002, 55 (02) : 191 - 203
  • [10] Janda K.D., 1997, Patent, Patent No. 9735199